Non-metastatic cells 1 (NME1), also known as NM23-H1, originally identified as a candidate metastasis suppressor gene. NME1 is expressed in different tumor types where their levels have been alternatively associated with reduced or increased metastatic potential. Reductions in NME1 expression have been significantly associated with aggressive behavior in melanoma, breast, colon, and gastric carcinomas. On the contrary, high levels of NME1 gene expression are noted in the advanced stage of thyroid carcinomas. Recombinant human NME1 was expressed in E. coli and purified by using conventional chromatography techniques. Alternative Names: NM23-H1 protein, NDP Kinase A protein, NME-1 protein, NM23H1B protein, NM23 long variant protein, Nonmetastatic protein 23 protein, protein expressed in protein, Granzyme A activated DNase protein, GZMA activated DNase protein, AWD protein, Nucleoside diphosphate kinase A protein, NDK A protein, NME-1, Nonmetastatic cells 1 protein, Non-metastatic cells 1 AWD protein, GAAD protein, included protein, Tumor metastatic process-associated protein., NDP kinase A protein, included protein, drosophila protein, included protein, NB protein, Nonmetastatic protein 23 protein, NME1-NME2 spliced read-through transcript protein, NME 1 protein, NM23 protein, NDPK-A protein, Metastasis inhibition factor nm23 protein, NBS protein, NM23-M1 protein, protein (NM23A) expressed in protein, NM23 protein, homolog of protein, homolog 1 protein, NME 1, NDPKA protein, NME1, Nucleoside diphosphate kinase A protein, NME1 protein, Non-metastatic cells 1 protein